RxDoctor Payments Data

Michael Matthews

Neurology · Greenville, PANPI 1023083755

Payments from drug & device makers

$25,983in general payments, 2019–2025

Across 66 payments — averaging $393.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$25K
  • Teva Pharmaceuticals USA, Inc.$250
  • Neurelis, Inc.$227
  • SK Life Science, Inc.$204
  • Bristol Myers Squibb$188
  • Genentech USA, Inc.$115
  • plus $445 from 9 others

What the payments were for

  • Consulting fees$2,2479%
  • Speaking & faculty fees$19,75676%
  • Food & beverage$3,95315%
  • Education$280%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,983 in reported general payments places this provider in the 80th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$48,363
Medicare patients
258
Services billed
385

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RebifInterferon Beta-1a/Albumin13$134,517
ZeposiaOzanimod Hydrochloride13$117,875
Aimovig AutoinjectorErenumab-Aooe76$63,705
Teriflunomide15$57,094
KeppraLevetiracetam17$29,960
Dimethyl Fumarate39$26,277
Nurtec OdtRimegepant Sulfate16$24,046
Oxtellar XrOxcarbazepine11$21,280
RexultiBrexpiprazole12$19,760
AptiomEslicarbazepine Acetate12$15,642
Dalfampridine ErDalfampridine18$10,184
Emgality PenGalcanezumab-Gnlm14$10,003
Propranolol Hcl ErPropranolol Hcl190$7,304
Levetiracetam233$7,060
Lacosamide28$4,644

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
EMD Serono, Inc.Rebif$32$134,51713 claims
E.r. Squibb & Sons, L.L.C.Zeposia$45$117,87513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 941 neurology providers in Pennsylvania.

Other neurology in Greenville

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →